Madrigal Pharmaceuticals, Inc.
MDGL· Nasdaq
Released May 7, 2024, before the open
10-Q filed May 7, 2024, 37 days after period end · 0001628280-24-020865
| Metric | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$147.54M | -$76.90M | -$57.52M | -$52.55M |
| EPS Diluted |
Madrigal Pharmaceuticals, Inc. · CIK 1157601 · Engraved from SEC EDGAR
| -$7.38 |
| -$4.23 |
| -$3.36 |
| -$3.32 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.